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Abstract Human VQ9/VN2 T cells play a crucial role in the
immune response to microbial pathogens, yet their unconven-
tional reactivity towards non-peptide antigens has been enig-
matic until recently. The break-through in identi¢cation of the
speci¢c activator was only possible due to recent success in
a seemingly remote ¢eld: the elucidation of the reaction steps
of the newly discovered 2-C-methyl-D-erythritol-4-phosphate
(MEP) pathway of isoprenoid biosynthesis that is utilised by
many pathogenic bacteria. Unexpectedly, the intermediate of
the MEP pathway, (E)-4-hydroxy-3-methyl-but-2-enyl-pyro-
phosphate) (HMB-PP), turned out to be by far the most potent
VQ9/VN2 T cell activator known, with an EC50 of 0.1 nM.
2 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
In humans, QN T cells constitute 0.5^15% of peripheral
blood T cells and comprise a number of subpopulations char-
acterised by the distinct repertoire of antigen receptors en-
coded by VQ- and VN-gene segments. Speci¢c activation and
oligoclonal expansion of QN T cells bearing a VQ9/VN2 T cell
receptor is observed after infection with a broad range of
microbial pathogens, and considered crucial for the regulation
of the immune response in diseases like tuberculosis or ma-
laria. While the response of VQ9/VN2 T cells depends on the
expression of a functional VQ9/VN2 T cell receptor on the
surface, it does not require classical antigen presentation in
the context of the major histocompatibility complex, as op-
posed to the conventional recognition of small antigenic pep-
tides by KL T cells. Also, the unique reactivity of VQ9/VN2 T
cells towards low molecular weight compounds (6 1 kDa)
that are resistant against proteinase K treatment but suscep-
tible to degradation by alkaline phosphatase has long puzzled
immunologists, even more so as it seems to be restricted to
humans and higher primates [1^4]. Strikingly, the most recent
identi¢cation of the speci¢c and naturally occurring activator
of human VQ9/VN2 T cells and the elucidation of the terminal
reaction steps in a newly discovered, alternative pathway of
isoprenoid biosynthesis went hand in hand.
2. The MEP pathway of isoprenoid biosynthesis
Isoprenoids are essentially involved in primary and second-
ary metabolism, and include such diverse molecules as sterols,
dolichols, plastoquinones, ubiquinones, carotenoids, and the
prenyl side chains of chlorophylls. However, despite their
structural and functional variety, all isoprenoids derive from
a common precursor, isopentenyl pyrophosphate (IPP), and
its isomer, dimethylallyl pyrophosphate (DMAPP). Until very
recently, IPP was thought to be synthesised exclusively via the
so-called mevalonate pathway, with 3-hydroxy-3-methylglu-
taryl-CoA (HMG-CoA) reductase as the key regulatory en-
zyme. The reaction steps of the mevalonate pathway of iso-
prenoid biosynthesis were ¢rst demonstrated in mammalian
cells and yeast, but soon accepted to be universal in all or-
ganisms [5]. Yet unexpectedly, the existence of a second iso-
prenoid pathway was discovered in 1993 during isotope incor-
poration studies in a number of bacteria and plant species
[6^9] ; this pathway was later named after its key intermediate,
the 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway. It
has now become clear that in eukaryotes, archaebacteria,
and certain eubacteria, biosynthesis of IPP and DMAPP pro-
ceeds entirely via the classical mevalonate pathway, while in
many eubacteria and the plastids of algae and higher plants,
IPP and DMAPP are supplied by the MEP pathway [10^12].
Also, apicomplexan protozoa like the malarial parasites har-
bour the MEP pathway in a plastid-like organelle, the apico-
plast [13].
Pioneer work postulated the formation of 1-deoxy-D-xylu-
lose 5-phosphate (DOXP) from pyruvate and glyceraldehyde
3-phosphate as the starting point of the alternative non-me-
valonate pathway of isoprenoid biosynthesis, and accordingly
identi¢ed the responsible enzyme, DOXP synthase (Dxs), by
its homology to known transketolases [14,15]. Subsequent in-
vestigations could reveal that DOXP is then converted into
MEP by DOXP reductoisomerase (Dxr, IspC) [16^18]. (It is
worth stressing that apart from being involved in the MEP
pathway, DOXP is also a precursor of thiamine and pyridox-
al, thus making MEP the ¢rst true intermediate of the alter-
0014-5793 / 03 / $22.00 I 2003 Published by Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies.
doi:10.1016/S0014-5793(03)00483-6
*Corresponding author. Fax: (49)-641-99 47499.
E-mail address: matthias.eberl@biochemie.med.uni-giessen.de
(M. Eberl).
Abbreviations: DMAPP, dimethylallyl pyrophosphate; DOXP, 1-de-
oxy-D-xylulose 5-phosphate; Dxr, 1-deoxy-D-xylulose 5-phosphate
reductoisomerase; Dxs, 1-deoxy-D-xylulose 5-phosphate synthase;
HMB-PP, (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate; HMG-
CoA, 3-hydroxy-3-methylglutaryl-CoA; IPP, isopentenyl pyrophos-
phate; MEcPP, 2-C-methyl-D-erythritol 2,4-cyclopyrophosphate;
MEP, 2-C-methyl-D-erythritol 4-phosphate
FEBS 27286 21-5-03
FEBS 27286FEBS Letters 544 (2003) 4^10
native pathway of isoprenoid biosynthesis, and justifying the
now commonly accepted reference as to the MEP pathway.)
Finally, the enzymes encoded by the genes ygbP (ispD), ychB
(ispE), and ygbB (ispF) were shown to mediate the subsequent
formation of 2-C-methyl-D-erythritol 2,4-cyclopyrophosphate
(MEcPP) via three consecutive reaction steps [19^21] (Fig. 1).
Despite this rapid progress, the biochemical conversion of
MEcPP into IPP and DMAPP has only now been understood.
An additional role for the genes gcpE (ispG) and lytB (ispH)
in IPP formation via the MEP pathway was demonstrated
using knock-out techniques. Escherichia coli strains de¢cient
in gcpE and lytB, respectively, that utilise exogenously pro-
vided mevalonate for IPP synthesis were created by comple-
mentation with plasmids expressing the heterologous enzymes
of the mevalonate pathway. In consequence, the mutants were
only viable when the culture medium was supplemented with
mevalonate, thereby by-passing the defect in IPP formation,
whereas under normal circumstances de¢ciency in either gcpE
or lytB was lethal [22^24]. In other studies, addition of the
alcohol analogues of IPP and DMAPP (3-methyl-3-buten-1-ol
and 3-methyl-2-buten-1-ol, respectively) was necessary to sup-
port the growth of lytB-de¢cient mutants of E. coli and the
cyanobacterium Synechocystis [25,26]. However, the enzy-
matic activity of the corresponding enzymes GcpE and LytB
could not be resolved by these studies, and the gap between
MEcPP and IPP still needed to be ¢lled.
3. Identi¢cation of (E)-4-hydroxy-3-methyl-but-2-enyl
pyrophosphate (HMB-PP) as the natural QN T cell activator
Although IPP was isolated from Mycobacterium smegmatis
as the ¢rst ‘natural ligand’ described for VQ9/VN2 T cells [27],
it soon became clear that the amounts of IPP present in bac-
terial extracts do not reach the minimum required for induc-
ing T cell activation [28]. Instead, the biosynthesis of IPP
could be implicated in VQ9/VN2 T cell reactivity. A compar-
ison between extracts from bacteria possessing the classical
mevalonate pathway of IPP synthesis, such as Lactobacillus
casei and Staphylococcus aureus, and bacteria possessing the
MEP pathway, such as E. coli and Corynebacterium ammonia-
genes, revealed that only the latter are capable of stimulating
VQ9/VN2 T cells in vitro [28]. The ¢nal proof that compounds
synthesised by the MEP pathway are indeed responsible for
this phenomenon, came from genetically engineered E. coli
strains, with essential enzymes of the MEP pathway being
disrupted or deleted from the genome. Low molecular weight
extracts prepared from vdxr and vgcpE mutants had a sig-
ni¢cantly reduced capacity to stimulate VQ9/VN2 T cells, com-
pared to the parent E. coli strain [29], thus proving the im-
portance of the MEP pathway for biosynthesis of the QN T cell
activator. Addition of 2-C-methyl-D-erythritol to the bacteria
broth by-passed the de¢ciency in dxr [30], and consequently
restored the immunogenicity [29]. However, none of the
known intermediates DOXP, MEP, CDP-ME (4-diphospho-
cytidyl-2-C-methyl-D-erythritol), CDP-MEP (4-diphosphocy-
tidyl-2-C-methyl-D-erythritol 2-phosphate), and MEcPP ex-
erted any T cell stimulatory activity [28,31^33].
In striking contrast to the case of vdxr and vgcpE mutants,
extracts from vlytB bacteria were highly immunogenic, and
the VQ9/VN2 T cell-stimulating molecule accumulated by a
factor of approx. 150, compared to wild-type E. coli [34].
The compound accounting for the strong bioactivity of the
vlytB mutant was characterised as a small pyrophosphory-
lated compound with a molecular mass of 262 Da, and puri-
¢ed by preparative anion exchange chromatography. Subse-
quently, the substance obtained was identi¢ed by electrospray-
Fig. 1. The reaction steps of the MEP pathway of isoprenoid bio-
synthesis.
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ionisation mass spectroscopy, 1H, 13C and 31P nuclear mag-
netic resonance (NMR) spectroscopy, and NOESY (nuclear
Overhauser e¡ect spectroscopy) analysis as HMB-PP [35]. At
that time, HMB-PP was a novel metabolite that had not been
described before, and turned out to be approx. 10 000 times
more potent in stimulating VQ9/VN2 T cells than IPP.
Although there was only little evidence that HMB-PP was a
true intermediate of the MEP pathway and not merely a side-
product, the chemical structure of HMB-PP was in accor-
dance with incorporation studies using deuterium-labelled
methyl erythritol isotopomers [36], and insinuated a plausible
mechanism for the unclear biosynthetic reaction sequence
from MEcPP to IPP. In earlier studies, a highly immunogenic
molecule of 262 Da with a comparable bioactivity had already
been isolated from di¡erent mycobacterial species [37,38], and
later from E. coli [32]. However, the chemical structure de-
scribed as 3-formyl-1-butyl pyrophosphate (FBPP, TUBag1)
has to remain speculative as the NMR data available di¡ered
from those of related compounds [35]. The existence of FBPP
was mainly deduced from mass spectrometry analyses that
rather suggest that the compound puri¢ed was actually
HMB-PP, which results in an identical fragmentation pattern.
Since its ¢rst isolation from vlytB E. coli cells, the chemical
synthesis of HMB-PP has been achieved by a number of lab-
oratories [33,39^44]. Importantly, synthetic HMB-PP and the
natural compound isolated from E. coli vlytB mutants dis-
played identical activities in stimulating VQ9/VN2 T cells [33^
35]. The reactivity of human peripheral blood mononuclear
cells towards HMB-PP was restricted to VQ9/VN2 T cells, lead-
ing to up-regulation of activation markers on the cell surface,
secretion of pro-in£ammatory cytokines, and expansion of the
VQ9/VN2 subpopulation in the presence of co-stimulation pro-
vided by interleukin-2 [33^35,45] (Fig. 2). In long-term VQ9/
VN2 T cell lines, HMB-PP triggered sustained T cell receptor
signalling (Lafont, V. and Eberl, M., unpublished). While the
observed e¡ects were in line with earlier investigations on the
weak agonist IPP, HMB-PP had an EC50 value of approx. 0.1
nM (compared to IPP with an EC50 of approx. 1 WM) [33],
making HMB-PP by far the most potent and speci¢c activator
known for VQ9/VN2 T cells [46]. Thus, it is likely that in fact
HMB-PP exclusively accounts for the well-described VQ9/VN2
T cell reactivity towards pathogenic bacteria such as Brucella,
Campylobacter, Ehrlichia, E. coli, Francisella, Listeria, Myco-
bacterium, Pseudomonas, Salmonella, and Yersinia, as well as
to the protozoan parasites Plasmodium and Toxoplasma (re-
viewed in [47]), in all of which the genes of the MEP pathway
can be identi¢ed (Table 1).
4. Veri¢cation of HMB-PP as the missing link in the MEP
pathway
As vgcpE mutants did not display any VQ9/VN2 T cell bio-
activity, GcpE was deduced to come ¢rst within the reaction
sequence of the MEP pathway, before LytB [29,34]. More-
over, the fact that vgcpE and vlytB E. coli mutants accu-
mulated MEcPP and HMB-PP, respectively, suggested these
metabolites to represent the putative substrates of the cor-
responding enzymes [29,34,48]. Also, production of a phos-
phorylated derivative of (E)-2-methylbut-2-ene-1,4-diol (most
likely representing HMB-PP) from radioactively labelled
MEcPP was observed in crude extracts of E. coli cells over-
expressing the three genes yfgA, yfgB and gcpE, which appear
in a single gene cluster on the E. coli chromosome [49]. In
analogous studies, in E. coli cells over-expressing all genes of
the MEP pathway from dxs down to gcpE on a single arti¢cial
operon, enrichment of HMB-PP could be detected in the
bacterial lysate [50]. Similarly, the production of IPP and
DMAPP was observed when in addition the operon also in-
cluded the lytB gene [51], indicating that HMB-PP indeed
represented the long-sought missing link in the reaction se-
quence between MEcPP and IPP.
Eventually, an active recombinant GcpE from the hyper-
thermophilic bacterium Thermus thermophilus could be suc-
cessfully expressed in E. coli and puri¢ed under oxygen-free
Fig. 2. Activation of human peripheral blood mononuclear cells by HMB-PP. Human peripheral blood mononuclear cells were labelled with
5-(and 6-)carboxy£uorescein diacetate succinimidyl ester (CFSE) and incubated with 0.25 nM HMB-PP in the presence of 100 U/ml interleu-
kin-2 [45]. After 4, 5, and 6 days, cells were stained with CD3-phycoerythrin-Texas Red and VQ9-phycoerythrin-cyanin 5.1 monoclonal anti-
bodies, and dilution of the CFSE signal was measured in the VQ9þ CD3þ ( =VQ9/VN2 T cells) and VQ93 CD3þ gate ( =mainly CD4þ and
CD8þ KL T cells). Control, cells incubated for six days in the absence of HMB-PP.
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Table 1
The MEP pathway in human pathogenic, opportunistic, and commensal microbes
Species dxs dxr ygbP ychB ygbB gcpE lytB
Acinetobacter sp. ? ? ? ? ? ? +
Actinobacillus pleuropneumoniaeb + + + + + + +
Actinobacillus actinomycetemcomitansb + + + + + + +
Anaplasma phagocytophilumb + + + + + + +
Bacillus anthracisa + + + + + + +
Bacillus cereusb + + + + + + +
Bacteroides fragilisb + + + ? + + +
Bacteroides thetaiotaomicrona + + + + + + +
Bi¢dobacterium longumb + + + + + + +
Bordetella bronchisepticab + + + + + + +
Bordetella pertussisb + + + + + + +
Brucella melitensisa + + + + + + +
Brucella suisa + ? + + + + +
Burkholderia cepaciab + + + + + + +
Burkholderia malleib + + + + + + +
Burkholderia pseudomalleib + + + + + + +
Campylobacter jejunia + + + + + + +
Chlamydia trachomatisa + + + + + + +
Chlamydophila pneumoniaea + + + + + + +
Clostridium botulinumb + + + + + + +
Clostridium perfringensa + + + + + + +
Clostridium di⁄cileb + + + + + + +
Clostridium tetania + + + + + + +
Corynebacterium diphtheriaeb + + + + + + +
Ehrlichia cha¡eensisb + + + + + + +
Escherichia colia + + + + + + +
Eubacterium sp. ? ? ? ? ? ? ?
Francisella tularensisb + + + + + + +
Fusobacterium nucleatumb + + + + + + +
Gardnerella vaginalis ? ? ? ? ? ? ?
Haemophilus ducreyib + + + + + + +
Haemophilus in£uenzaea + + + + + + +
Helicobacter pyloria + + + + + + +
Klebsiella pneumoniaeb + + + ? + + ?
Leptospira interrogansa + + + + + + +
Listeria monocytogenesa + + + + + + +
Mannheimia haemolyticab + + + + + + +
Moraxella catarrhalisa + + + + + + +
Mycobacterium lepraea + + + + + + +
Mycobacterium smegmatisb + + + + + + +
Mycobacterium tuberculosisa + + + + + + +
Mycoplasma penetransb + + + ? + + +
Neisseria gonorrhoeaeb + + + + + + +
Neisseria meningitidisa + + + + + + +
Neorickettsia sennetsub + + + + + + +
Pasteurella multocidaa + + + + + + +
Peptostreptococcus sp. ? ? ? ? ? ? ?
Porphyromonas gingivalisb + + + + + + +
Prevotella intermediab + + + + + + +
Proteus mirabilis ? ? ? ? ? ? ?
Providencia stuartii ? ? ? ? ? + ?
Pseudomonas aeruginosaa + + + + + + +
Pseudomonas putidaa + + + + + + +
Psychrobacter sp.b + + ? + + + +
Salmonella entericaa + + + + + + +
Salmonella enteritidisb + + + + + + +
Salmonella typhimuriuma + + + + + + +
Serratia marcescensb + + + + + + +
Shewanella putrefaciensb + + + + + + +
Shigella £exneria + + + + + + +
Shigella dysenteriaeb + + + + + + +
Tannerella forsythensisb + + + + + + +
Treponema denticolab + + + + + + +
Treponema palliduma + + + + + + +
Tropheryma whippleia + + + + + + +
Vibrio choleraea + + + + + + +
Vibrio vulni¢cusa + + + + + + +
Wolbachia sp.b + + + + + + +
Yersinia pestisa + + + + + + +
Yersinia enterocoliticab + + + + + + +
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conditions. In an in vitro assay, this protein was enzymatically
active and converted MEcPP into HMB-PP in the presence of
dithionite as reducing agent [52]. Other investigators expressed
a fusion protein encompassing the E. coli GcpE and a mal-
tose-binding domain, and demonstrated that, whereas the pu-
ri¢ed protein was inactive, the described activity could be
restored by addition of a crude cell extract from a vgcpE
mutant, suggesting the requirement of auxiliary factors
present in bacterial extract [53]. Similarly, while a fusion pro-
tein of the E. coli LytB protein and the maltose-binding do-
main was unable to catalyse the in vitro transformation of
HMB-PP, the recombinant protein increased the low intrinsic
catalytic activity of E. coli wild-type extract [54]. During the
course of these studies, HMB-PP was shown by in vitro and
in vivo experiments to serve as the biosynthetic precursor of
both IPP and DMAPP, which were obtained in a ratio of
4:1^6:1 by the catalytic action of LytB [51,53,54]. The appar-
ent formation of IPP and DMAPP by a single enzyme was in
remarkable contrast to the mevalonate pathway where
DMAPP is successively synthesised from IPP by IPP isomer-
ase. Yet, branching of the MEP pathway for the formation of
IPP and DMAPP had already been suggested earlier based on
isotope-labelling experiments and the fact that E. coli deletion
mutants for IPP isomerase were still viable, while a lytB de-
¢ciency was lethal [24^26,55] ; even more, many bacteria with
the MEP pathway do not possess IPP isomerases [12]. In a
de¢ned in vitro assay under exclusion of oxygen, incubation
of recombinant LytB from the thermophilic bacterium Aqui-
fex aeolicus with HMB-PP and dithionite as arti¢cial electron
donor resulted in the formation of IPP and DMAPP at a ratio
of approx. 5:1 [56].
Only now can be appreciated why the investigation of the
terminal reaction steps has been hampered for so long. Both
GcpE and LytB contain [4Fe^4S] clusters and are therefore
highly oxygen sensitive, which had already been predicted
from the existence of three conserved cysteine residues [43].
The presence of these clusters was evidenced by the observa-
tion that recombinant GcpE and LytB displayed typical ab-
sorptions at 413^420 nm in their UV/visible spectra [52,53,56],
and by data obtained by electron paramagnetic resonance
spectroscopy (Duin, E.C., Altincicek, B. and Kollas, A.K.,
unpublished). Additional support for such a prosthetic group
was provided by the successful in vitro reconstitution of the
[4Fe^4S] cluster of E. coli GcpE and its enzymatic activity
using photoreduced 5-deaza£avin or a £avodoxin/£avodoxin
reductase regeneration system [57]. Although the natural co-
factors and electron donors for GcpE and LytB still need to
be found, the main steps of the MEP pathway can thus be
considered cracked.
5. Conclusions
With the enzymes and intermediates of the MEP pathway
being identi¢ed, it is becoming increasingly clear that this
reaction cascade is more than merely an alternative pathway
of isoprenoid biosynthesis. Apart from its relevance for iso-
prenoid biosynthesis, some intermediates of the pathway can
also serve as substrates for other pathways branching o¡ the
isoprenoid mainline. While DOXP is also a precursor of thi-
amine and pyridoxal, it has recently been shown that HMB-
PP is used for the synthesis of the plant hormone zeatin by
Agrobacterium tumefaciens [58]. In contrast, the physiological
role for the apparent occurrence of uridine- and thymidine-
conjugates of HMB-PP in mycobacteria is not clear yet
[38,59]. Whether HMB-PP is involved in further biosynthetic
functions and whether other metabolites also play additional
roles remains to be clari¢ed. Still, the involvement of the MEP
pathway in providing the VQ9/VN2 T cell activator is the most
intriguing outcome of these biochemical studies.
The highly speci¢c reactivity of VQ9/VN2 T cells has now
been resolved, but its biological implication still poses a num-
ber of questions. VQ9/VN2 T cells have manifold functions and
exhibit the classical type 1/type 2 cytokine dichotomy already
established for CD4 and CD8 T cells [60]. Also, the existence
of naive, e¡ector memory, and central memory VQ9/VN2 T
cells parallels ¢ndings on CD4 and CD8 T cells [45]. But
what is the precise role of these multipotent T cell popula-
tions? And why does the e⁄cient recognition of low molec-
ular weight compounds not exist in other mammalians, with
QN T cells being supposedly the ¢rst step in the evolution of
adaptive immunity more than 400 million years ago [61]?
Some authors suggested that a major function of VQ9/VN2 T
cells might be scrutinising the body for transformed cells that
are metabolically altered and display an imbalanced IPP bio-
synthesis. Thus, damaged or necrotic cells might release IPP
or higher isoprenoid units like farnesyl-PP or geranyl-PP dur-
ing the course of viral, bacterial or parasitic infections [62].
Also, the (hypothetical) accumulation of these relatively poor
ligands might represent some kind of ‘danger’ signal for the
immune system [63] (although the inhibitory e¡ect of mevas-
tatin and other HMG-CoA reductase blockers on VQ9/VN2 T
cell activation might be mediated through in£uencing post-
translational isoprenylation of proteins involved in cell divi-
sion and maturation, rather than IPP depletion [64]). At the
same time it is thinkable that recognition of HMB-PP and
related compounds by VQ9/VN2 T cells is a mechanism devel-
oped during primate evolution to allow a speci¢c but broad
reactivity towards many microbial pathogens, by targeting a
distinctive and vital metabolic route shared by these organ-
Table 1 (Continued).
Species dxs dxr ygbP ychB ygbB gcpE lytB
Cryptosporidium parvum + ? + ? + + ?
Plasmodium falciparuma + + + + + + +
Plasmodium vivaxb + + + + + + +
Toxoplasma gondii + + ? ? + + +
Homologues to E. coli genes were identi¢ed by TBLASTN searches at www.ncbi.nlm.nih.gov, www.tigr.org, www.jgi.doe.gov, www.parvum.
mic.vcu.edu, www.genedb.org, hgsc.bcm.tmc.edu, and artedi.ebc.uu.se. In some species (e.g. B. suis, B. melitensis, C. jejuni, H. pylori, T. pallid-
um, T. whipplei, and others), ygbP and ygbB are within the same open reading frame and encode a YgbP^YgbB fusion protein. M. penetrans is
the only Mycoplasma species sequenced so far having the MEP pathway, which is absent in M. genitalium, M. pneumoniae, and M. pulmonis.
L. monocytogenes harbours both the MEP and the mevalonate pathway.
aComplete genome available.
bWhole genome shotgun sequence available.
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isms ^ most human pathogens possess the MEP pathway
(with Streptococcus, Staphylococcus and Borrelia being the
main exceptions). Due to this unconventional recognition pat-
tern, VQ9/VN2 T cells would not need to tra⁄c through lym-
phoid organs where only rare antigens have to be processed
and presented to highly speci¢c cognate antigen receptors [65].
Still, if VQ9/VN2 T cells evolved to detect both stressed cells
and microbial pathogens, this could only be achieved if the
local amounts of IPP released from damaged tissues were
some 10 000-fold higher than the HMB-PP concentrations
reached during bacterial infections, to allow for the hugely
di¡erent bioactivities of these two compounds.
In many cases though, the rapid and strong reactivity of
VQ9/VN2 T cells towards HMB-PP seems somewhat ine¡ec-
tive, as many bacterial species manage to escape the immune
response nonetheless and establish chronic and debilitating
infections ^ among these are some of the oldest and severest
infectious diseases of humans, such as tuberculosis, leprosy,
syphilis, and malaria. Even more, why have these pathogens
not succeeded in avoiding the suicidal presentation of such a
highly immunogenic compound to the host’s immune system?
Importantly, not only do many pathogenic and opportunistic
bacteria use the MEP pathway, but also the most frequent
bacteria species in the enteric £ora and human faeces, Bacter-
oides, Bi¢dobacterium, Fusobacterium, E. coli, and Clostridium
(and probably also Eubacterium and Peptostreptococcus).
Thus, VQ9/VN2 T cells are more likely to play a role in main-
taining the physiological function of the intestine and might
primarily have evolved to initiate and regulate the mucosal
immune system in order to limit a detrimental host response
towards commensal bacteria. If this is the case, do pathogens
then deliberately exploit this surveillance system during in¢l-
tration of the body, thereby inducing a state of tolerance?
Basically, it still remains puzzling how a molecule as simple
as HMB-PP can be recognised with such a high speci¢city by
the VQ9/VN2 T cell receptor, and how ^ if at all ^ the host
bene¢ts from this property in microbial infection.
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